Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel

Abstract The usage of direct oral anticoagulants (DOACs) to prevent and treat thromboembolic events is gradually increasing. We aimed to evaluate the outcomes of patients taking DOACs after polypectomy. We retrospectively reviewed 131 patients taking DOACs and 270 taking clopidogrel who underwent po...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gwang-Un Kim, Sinwon Lee, Jaewon Choe, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Dong-Hoon Yang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/61f16ef40066406c82bfbb1b3e96c424
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61f16ef40066406c82bfbb1b3e96c424
record_format	dspace
spelling	oai:doaj.org-article:61f16ef40066406c82bfbb1b3e96c4242021-12-02T10:48:31ZRisk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel10.1038/s41598-021-82251-y2045-2322https://doaj.org/article/61f16ef40066406c82bfbb1b3e96c4242021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82251-yhttps://doaj.org/toc/2045-2322Abstract The usage of direct oral anticoagulants (DOACs) to prevent and treat thromboembolic events is gradually increasing. We aimed to evaluate the outcomes of patients taking DOACs after polypectomy. We retrospectively reviewed 131 patients taking DOACs and 270 taking clopidogrel who underwent polypectomy between November 2010 and December 2017. The risk of delayed postpolypectomy bleeding (PPB) was evaluated and compared. A total of 989 polyps were removed (320 polyps in the DOAC and 669 polyps in the clopidogrel group). DOACs and clopidogrel were discontinued for 2.8 ± 1.7 days and 5.8 ± 2.5 days before polypectomy, respectively. DOACs and clopidogrel were restarted on 1.6 ± 2.9 days and 1.7 ± 1.1 days after polypectomy, respectively. According to per polyp analysis, delayed PPB rate was 1.6% in both groups (p = 0.924). Logistic regression analysis was performed after propensity score matching and revealed that DOACs did not increase the delayed PPB risk compared to clopidogrel (OR 0.929, 95% CI 0.436–1.975, p = 0.847). With the majority following the antithrombotic discontinuation guidelines, the incidence of delayed PPB was 3.1% in the patients taking DOACs. The delayed PPB risk was not greater in those taking DOACs than in those taking clopidogrel.Gwang-Un KimSinwon LeeJaewon ChoeSung Wook HwangSang Hyoung ParkByong Duk YeJeong-Sik ByeonSeung-Jae MyungSuk-Kyun YangDong-Hoon YangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Gwang-Un Kim Sinwon Lee Jaewon Choe Sung Wook Hwang Sang Hyoung Park Byong Duk Ye Jeong-Sik Byeon Seung-Jae Myung Suk-Kyun Yang Dong-Hoon Yang Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
description	Abstract The usage of direct oral anticoagulants (DOACs) to prevent and treat thromboembolic events is gradually increasing. We aimed to evaluate the outcomes of patients taking DOACs after polypectomy. We retrospectively reviewed 131 patients taking DOACs and 270 taking clopidogrel who underwent polypectomy between November 2010 and December 2017. The risk of delayed postpolypectomy bleeding (PPB) was evaluated and compared. A total of 989 polyps were removed (320 polyps in the DOAC and 669 polyps in the clopidogrel group). DOACs and clopidogrel were discontinued for 2.8 ± 1.7 days and 5.8 ± 2.5 days before polypectomy, respectively. DOACs and clopidogrel were restarted on 1.6 ± 2.9 days and 1.7 ± 1.1 days after polypectomy, respectively. According to per polyp analysis, delayed PPB rate was 1.6% in both groups (p = 0.924). Logistic regression analysis was performed after propensity score matching and revealed that DOACs did not increase the delayed PPB risk compared to clopidogrel (OR 0.929, 95% CI 0.436–1.975, p = 0.847). With the majority following the antithrombotic discontinuation guidelines, the incidence of delayed PPB was 3.1% in the patients taking DOACs. The delayed PPB risk was not greater in those taking DOACs than in those taking clopidogrel.
format	article
author	Gwang-Un Kim Sinwon Lee Jaewon Choe Sung Wook Hwang Sang Hyoung Park Byong Duk Ye Jeong-Sik Byeon Seung-Jae Myung Suk-Kyun Yang Dong-Hoon Yang
author_facet	Gwang-Un Kim Sinwon Lee Jaewon Choe Sung Wook Hwang Sang Hyoung Park Byong Duk Ye Jeong-Sik Byeon Seung-Jae Myung Suk-Kyun Yang Dong-Hoon Yang
author_sort	Gwang-Un Kim
title	Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
title_short	Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
title_full	Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
title_fullStr	Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
title_full_unstemmed	Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
title_sort	risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/61f16ef40066406c82bfbb1b3e96c424
work_keys_str_mv	AT gwangunkim riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT sinwonlee riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT jaewonchoe riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT sungwookhwang riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT sanghyoungpark riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT byongdukye riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT jeongsikbyeon riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT seungjaemyung riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT sukkyunyang riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel AT donghoonyang riskofpostpolypectomybleedinginpatientstakingdirectoralanticoagulantsorclopidogrel
_version_	1718396649814884352

Risk of postpolypectomy bleeding in patients taking direct oral anticoagulants or clopidogrel

Ejemplares similares